Restoration of aberrant gene expression of monocytes in systemic lupus erythematosus via a combined transcriptome-reversal and network-based drug repurposing strategy.
Drug repurposing
Micro RNAs
Monocytes
Systemic lupus erythematosus
Transcription factors
Journal
BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258
Informations de publication
Date de publication:
18 Apr 2023
18 Apr 2023
Historique:
received:
24
08
2022
accepted:
27
03
2023
medline:
20
4
2023
pubmed:
19
4
2023
entrez:
18
04
2023
Statut:
epublish
Résumé
Monocytes -key regulators of the innate immune response- are actively involved in the pathogenesis of systemic lupus erythematosus (SLE). We sought to identify novel compounds that might serve as monocyte-directed targeted therapies in SLE. We performed mRNA sequencing in monocytes from 15 patients with active SLE and 10 healthy individuals. Disease activity was assessed with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K). Leveraging the drug repurposing platforms iLINCS, CLUE and L1000CDS Application of two independent - a transcriptome-reversal and a network-based -drug repurposing strategies uncovered novel agents that might remedy transcriptional disturbances of monocytes in SLE.
Sections du résumé
BACKGROUND
BACKGROUND
Monocytes -key regulators of the innate immune response- are actively involved in the pathogenesis of systemic lupus erythematosus (SLE). We sought to identify novel compounds that might serve as monocyte-directed targeted therapies in SLE.
RESULTS
RESULTS
We performed mRNA sequencing in monocytes from 15 patients with active SLE and 10 healthy individuals. Disease activity was assessed with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K). Leveraging the drug repurposing platforms iLINCS, CLUE and L1000CDS
CONCLUSIONS
CONCLUSIONS
Application of two independent - a transcriptome-reversal and a network-based -drug repurposing strategies uncovered novel agents that might remedy transcriptional disturbances of monocytes in SLE.
Identifiants
pubmed: 37072752
doi: 10.1186/s12864-023-09275-8
pii: 10.1186/s12864-023-09275-8
pmc: PMC10114456
doi:
Substances chimiques
NF-kappa B
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207Subventions
Organisme : European Research Council
ID : 742390
Pays : International
Informations de copyright
© 2023. The Author(s).
Références
Discov Med. 2010 Mar;9(46):173-8
pubmed: 20350481
J Autoimmun. 2017 May;79:105-111
pubmed: 28318807
Ann Rheum Dis. 2022 Jul 7;:
pubmed: 35798534
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F217-26
pubmed: 26911849
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Clin Biochem. 2022 Sep;107:55-61
pubmed: 35598633
Rheumatology (Oxford). 2011 May;50(5):982-8
pubmed: 21245073
Lancet. 2018 Oct 13;392(10155):1330-1339
pubmed: 30249507
Clin Immunol. 2002 Apr;103(1):54-62
pubmed: 11987985
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769069
Int Immunopharmacol. 2011 Sep;11(9):1319-26
pubmed: 21549858
Ann Rheum Dis. 2015 Jul;74(7):1474-8
pubmed: 25710470
Mediators Inflamm. 2014;2014:385297
pubmed: 25548434
Inflammopharmacology. 2020 Apr;28(2):401-424
pubmed: 31732838
J Immunol. 2002 Jan 1;168(1):9-12
pubmed: 11751940
Arthritis Rheum. 1998 Jul;41(7):1241-50
pubmed: 9663482
J Invest Dermatol. 2015 Aug;135(8):1986-1995
pubmed: 25826425
Nat Commun. 2021 Mar 31;12(1):1980
pubmed: 33790300
Genome Res. 2021 Apr;31(4):659-676
pubmed: 33674349
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S120-32
pubmed: 16273796
PLoS One. 2015 May 14;10(5):e0127361
pubmed: 25974040
Eur J Immunol. 2015 Jul;45(7):2028-41
pubmed: 25871979
Cell Mol Immunol. 2012 May;9(3):255-66
pubmed: 22543833
Nat Rev Immunol. 2014 Jun;14(6):392-404
pubmed: 24854589
Molecules. 2019 Jun 03;24(11):
pubmed: 31163672
Exp Biol Med (Maywood). 2016 Aug;241(14):1611-9
pubmed: 27190277
Arthritis Rheum. 2010 Jul;62(7):2086-92
pubmed: 20222110
Cell Syst. 2018 Jan 24;6(1):13-24
pubmed: 29199020
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Int J Mol Sci. 2021 Jan 27;22(3):
pubmed: 33514066
Lupus. 1999;8(3):227-33
pubmed: 10342716
Arthritis Rheum. 2003 Feb;48(2):495-506
pubmed: 12571860
Arch Immunol Ther Exp (Warsz). 2010 Oct;58(5):355-64
pubmed: 20676786
Lupus Sci Med. 2019 Aug 13;6(1):e000270
pubmed: 31497305
Arthritis Rheumatol. 2019 Sep;71(9):1400-1412
pubmed: 31385462
Autoimmun Rev. 2007 Aug;6(7):497-502
pubmed: 17643939
Front Pharmacol. 2022 Jan 21;13:805508
pubmed: 35126161
Clin Chem. 2006 Mar;52(3):504-10
pubmed: 16423909
Front Immunol. 2022 May 09;13:860726
pubmed: 35615355
Rheumatol Int. 2006 Mar;26(5):409-15
pubmed: 16189656
Front Immunol. 2019 May 24;10:1140
pubmed: 31178867
Sci Rep. 2019 Oct 29;9(1):15502
pubmed: 31664045
Clin Rheumatol. 2005 Apr;24(2):107-10
pubmed: 15818511
NPJ Syst Biol Appl. 2016;2:
pubmed: 28413689
J Immunol. 2019 Oct 1;203(7):1776-1785
pubmed: 31484727
BMC Rheumatol. 2021 Mar 30;5(1):15
pubmed: 33781343
PLoS One. 2022 Mar 10;17(3):e0263778
pubmed: 35271583
Ann Rheum Dis. 2022 Oct;81(10):1409-1419
pubmed: 35906002
Arthritis Rheum. 2008 May;58(5):1433-44
pubmed: 18438845
Clin Immunol. 2017 Dec;185:100-108
pubmed: 27570219
J Interferon Cytokine Res. 2011 Nov;31(11):803-12
pubmed: 21859344
Arthritis Rheumatol. 2019 Aug;71(8):1308-1318
pubmed: 30791224
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Rheumatology (Oxford). 2004 Sep;43(9):1121-8
pubmed: 15213333
Exp Mol Med. 2017 Sep 29;49(9):e381
pubmed: 28960214
J Immunol. 2009 Jan 15;182(2):1192-201
pubmed: 19124763
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526
Front Immunol. 2018 Sep 26;9:2189
pubmed: 30319641
Front Pharmacol. 2022 Sep 13;13:982238
pubmed: 36176425